Applicants : David M. Stern, et al.

U.S. Serial No: 09/687,528

Filed : October 13, 2000

Page 2

Please amend the subject application as follows:

In the specification:

Please add the Sequence Listing annexed hereto as **Exhibit C** to the specification.

In the claims:

Please cancel claims 6 and 9 without prejudice to applicants' right to pursue the subject matter thereof in a future application.

Please amend claim 3 as follows:

3. (Amended) A method for preventing exaggerated restenosis in a diabetic subject which comprises administering to the subject a therapeutically effective amount of soluble receptor for advanced glycation endproducts (sRAGE) so as to prevent exaggerated restenosis in the subject.

REMARKS

Claims 3-6, 9, and 11-14 are pending in the subject application. By this Amendment, applicants have cancelled claims 6 and 9 without prejudice or disclaimer and amended claim 3. Support for these amendments may be found *inter alia* in the specification at page 19, lines 27-30 and page 18, SEQ. I.D. NO.: 5. Applicants maintain that the amendment of claim 3 raises no issue of new matter and is fully supported by the specification as filed. Applicants respectfully request that this Amendment be entered. Upon entry of